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Abstract The p53 binding protein, termed p53BP2, was identi- 
fied as a protein interacting with protein phosphatase 1 (PP1) in 
the yeast two hybrid system. The interaction was confirmed by 
co-immunoprecipitation f p53BP2 with epitope-tagged PPI in 
vitro. The p53BP2-PP1 complex was stable to NaC! at concen- 
trations which dissociate the p53-p53BP2 complex, and the bind- 
ing of PPl  and p53 to p53BP2 was mutually exclusive. The region 
required for interaction with PP1 was shown to be contained 
within amino acids 297-431 of p53BP2 , which includes two 
ankyrin repeats. The phosphorylase phosphatase activity of PPI 
was inhibited by p53BP2 at nanomolar concentrations. These 
results suggest hat PP1 may be involved in dephosphorylation 
and regulation of p53 through interaction with p53BP2. 
Key words. p53; Protein phosphatase: Two-hybrid system; 
Human 
1. Introduction 
The p53 protein acts as a tumour suppressor, mutations in 
the gene encoding it being the most common genetic alteration 
in human cancer [1,2]. At the molecular level, p53 functions as 
a transcription factor which binds to DNA in a sequence- 
specific manner and can be activated by DNA damaging agents 
and oxidative stress. A number of genes have binding sites for 
p53 and the mRNA levels of certain genes, such as p21 wAF~ [3,4] 
have been shown to increase in a p53 dependent manner, while 
transcription of other genes is inhibited. Increases in the level 
of p53 lead to growth arrest, suggesting that the protein acts 
as a checkpoint control in the cell cycle regulating entry from 
GI  phase into S phase, p21 wAv~ , which has been implicated in 
the inhibition of chromosomal DNA replication, cdk2 cyclin- 
dependent kinases and cyclin D 1 are likely to be involved in this 
process [5,6]. There is evidence that p53 is regulated by phos- 
phorylation. Mutation of a phosphorylation site in the amino- 
terminal region reduces the ability of p53 to inhibit cell cycle 
progression [7], while mutation of the penultimate residue to 
the carboxy-terminus, which is phosphorylated by casein ki- 
nase II, inactivates the growth suppressor activity of p53 in 
rodent cell lines [8]. Protein kinase C and casein kinase II can 
activate the latent sequence-specific DNA binding function of 
p53 in vitro [9]. 
Protein phosphatase 1 (PPI) interacts with a variety of regu- 
latory subunits which may target it to specific locations in the 
cell, modulate its substrate specificity and allow its activity to 
be regulated by extracellular signals. These include the glycogen 
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binding subunits in skeletal muscle [10] and liver [11] which 
mediate the regulation of PP1 by the hormones insulin and 
adrenalin, the myosin binding subunits of skeletal [12] and 
smooth muscle [13], the cytosolic inhibitor proteins inhibitor-1, 
inhibitor-2 and DARPP-32 [14], and the nuclear proteins ds22 
[15] and NIPP-1 [16]. Ribosomal protein L5 has also recently 
been identified as a molecule that interacts with PP1 [17]. In an 
attempt to identify important novel regulatory subunits of PP1, 
we carried out a yeast two hybrid screen using the catalytic 
subunit of PP1y L. This identified several proteins, including 
human inhibitor-2 reported recently [18] and p53BP2 which we 
describe here. p53BP2 is one of two p53 binding proteins (des- 
ignated p53BP1 and p53BP2), which were identified using ex- 
pressed p53 in the yeast two hybrid system and shown to bind 
to wild type but not mutant p53 in vitro [19]. In this communi- 
cation we show that p53BP2 forms a near stoichiometric com- 
plex with PPI in vitro and modulates its activity towards certain 
substrates. 
2. Materials and methods 
2.1. General methods and the yeast two hybrid analysis 
Microbial strains, growth conditions and methods for the yeast wo 
hybrid screen were as previously described [18]. Oligonucleotides were 
synthesized by Miss Audrey Gough (University of Dundee) on an 
Applied Biosystems model 394 DNA synthesizer. DNA sequencing of
expression constructs was performed on an Applied Biosystems 373A 
automated DNA sequencer using Taq dye terminator cycle sequencing. 
2.2. Expression of GST-p53BP2 Jusion proteins 
EeoRI fragments from plasmids pACT-H1 and pACT-H8 contain- 
ing p53BP2 coding sequence were ligated into the EcoRI site ofplasmid 
pGEX-3X [20] to generate plasmids pGEX-H1 and pGEX-H8 contain- 
ing all the p53BP2 coding sequence present in the pACT plasmids. After 
sequencing the constructs, they were transformed into E. eoli BL21 
(DE3) pLysS cells. Single colonies were grown to an A595 of 0.5 in LB 
medium (500 ml) containing ampicillin (100/lg/ml) and chlorampheni- 
col (25 ¢tg/ml) at 37°C. IPTG was added to a final concentration f 30 
~tM and growth continued overnight at 28°C. Cells were harvested by 
centrifugation at 5000 x g for 10 rain at 4°C, then resuspended in 10 
ml of buffer A (50 mM Tris-HC1 pH 7.5, 1 mM DTT, 1 mM EDTA, 
0.1 mM EGTA, 100 mM NaC1, 1 mM benzamidiue, 0.1 mM phenyl- 
methylsulphonyl fluoride (PMSF), 0.1 mM tosylphenylalanylchloro- 
methylketone, 1% (v/v) Triton X-100) and sonicated for 4 × 10 s on ice 
using a Jencons probe sonicator (model GE 50). The lysate was centri- 
fuged at 48,000 × g for 20 rain at 4°C, then the supernatant decanted 
and added to 1 ml of GSH-agarose (Sigma) pre-equilibrated in the same 
buffer. After mixing for 1 h at 4°C, the suspension was added to a 
Poly-Prep column (Bio-Rad) and washed with the above buffer until 
no further protein eluted. The column was then washed with 5 ml of 
buffer A minus Triton X-100 and bound material eluted in buffer A 
containing 20 mM reduced glutathione (Sigma). Eluted protein was 
concentrated bycentrifugation through acentricon 30 membrane (Ami- 
con) and stored frozen at -70°C. 
The pGEX-HIA deletion construct was generated by excising a 
BamHI Pstl fragment from the pGEX-HI plasmid and cloning it into 
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the BamHI-PstI sites of plasmid pBluescript KS +. This construct was 
then digested with BamHI and the overhanging 5' ends filled-in with 
dNTPs using the Klenow fragment of DNA polymerase, prior to diges- 
tion with EcoRI. To produce an in-frame fusion, the resulting fragment 
was cloned into the BamHI (filled-in)-EcoRI sites of plasmid pGEX-3X 
generating plasmid pGEX-H lzl. Sequencing of this plasmid confirmed 
that it contained cDNA sequence coding for 193 amino acids of 
p53BP2, starting at the same position within the eDNA as pGEX-H 1, 
and did not encode the 98 amino acids normally found at the C- 
terminus of the protein. Expression and purification of the truncated 
protein was performed as for pGEX-H1 and pGEX-H8, except hat 
IPTG was added to a final concentration f 0.1 mM and expression was 
at 37°C for 3 h. These conditions were used to minimise degradation 
of the fusion protein which occurred on overnight incubation at lower 
temperatures. 
2.3. Construction and pur~)%ation of epitope-tagged PP1 Y t 
In order to add the epitope EFMPME(H) 6 to the C-terminus of 
human PPIz~, the complementary oligonucleotides 5'-GATCACAA- 
AGCAAGCAAAGAAAGAATTTATGCCGATGGAACACCAC- 
CACCACCACCACTAGA-3' and 5"-AGCTTCTAGTGGTGGTG- 
GTGGT GGTGTTCCATCGGCATAA~TTC' I~TGCTTGCT-  
TTGT-3' incorporating a BclI site (underlined) and a HindllI site 
(double underlined) were synthesized. They were phosphorylated with 
ATP at the 5" ends using T4 kinase, hybridised by heating in equimolar 
amounts in 50 mM Tris-HCl pH 8.0 to 95°C, allowed to cool to 60°C, 
maintained at 60-65°C for 2 h and then allowed to cool to room 
temperature, PPIy: cDNA in pBS vector [21,22] was cleaved with BclI 
and HindIII. The fragment containing the vector and the region coding 
for amino acids 1-317 of PPI?'L was purified by gel electrophoresis, 
eluted from the gel using a Spin-X column and then ligated to the 
hybridised oligonucleotides. The ligation mixture was used to trans- 
form E. coli JM109 and DNA from several transformants was exam- 
ined after gel electrophoresis and Southern blotting for hybridisation 
to the [y-32p]ATP-labelled oligonucleotides. Positive transformants 
were selected and sequenced. A NdeI-HindlIl fragment encoding 
PP1Ta-EFMPME(H)6 was cleaved from one transformant with the 
correct sequence and subcloned into the expression vector pCW [23] 
using the same restriction sites. The pCW-PP1y]-EFMPME(H)6 con- 
struct was transformed into E, coil BL21(DE3) and expressed as de- 
scribed for PP 1 ~1 in [22]. Purification of the His-tagged protein was by 
metal affinity chromotography. The E. coli extract containing the 
pCW- PPITj-EFMPME(H)o protein was made 1 mM in imidazole-HCl 
and 0.5 M in NaC1 and applied to a nickel-nitrilotriacetate-agarose 
column equilibrated in 50 mM Tris-HCl pH 7,5, 1 mM PMSF, 10 mM 
imidazole-HCl and 0.5 M NaCI. After washing in the same buffer until 
the absorbance of the eluate at 280 nm was <0.01, the column was 
washed with 50 mM Tris-HC] pH 7.5 containing 30 mM imidazole- 
HC1, 0.5 M NaCI, 0.03% (v/v) Brij 35 and PP1yI-EFMPME(H) 6 was 
eluted with 50 mM Tris-HC1 pH 7.5 containing 300 mM imidazole- 
HC1, 0.15 M NaC1, 0.03% (v/v) Brij 35, 2 mM MnCIz and 5% (v/v) 
glycerol. Fractions were analysed by SDS-PAGE gel electrophoresis 
and those containing virtually pure protein were pooled and dialysed 
at 0°C against 25 mM Triethanolamine-HC1 pH7.5, 1 mM MnCI2, 0.1 
mM EGTA, 0.2 M NaC1.0.03% (w/v) Brij 35, 0.1% (v/v) 2-mercap- 
toethanol and 50% (v/v) glycerol and stored at -20°C. 
2.4. Preparations of antibodies to the epitope EFMPME 
Hybridoma cells expressing monoclonal antibodies against a pol- 
yoma medium T epitope, which recognise the sequence EFMPME, 
were a kind gift from Professor Gernot Walter, University of Califor- 
nia, San Diego, USA [24]. The protein in the supernatant from the 
hybridoma cell culture was precipitated in 50% ammonium sulphate 
and the precipitate r dissolved inphosphate buffered saline to one tenth 
of the original volume and dialysed against he same buffer. The par- 
tially purified monoclonal antibodies to the EFMPME epitope were 
covalently attached to protein G-Sepharose (Pharmacia) using dimeth- 
ylpimelimidate (Sigma) [25] and the resulting matrix stored at 4°C. 
2.5. Expression and pur~cation ~[ wild-type human p53 in E. coil 
Full length wild-type human p53 expressed in E. coli was purified as 
in [26] with the exception that gel filtration was not performed. 0.5 mg 
of approximately 20% pure p53 was isolated from 2 L of bacterial 
culture. 
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Fig. 1. lmmunoprecipitation f p53BP2 from E. coil extracts with 
epitope-tagged PP1 gj. 100 pl aliquots (0.3 mg protein) ofE. coli extracts 
expressing GST at approximately 150 pg/ml were prepared. Varying 
amounts of pure GST-p53BP2 (expressed from the GST-H1 clone) and 
2 pg of epitope-tagged PPIT~ were added and immunoprecipitations 
performed as described in section 2. Pellet and supernatant (10 ,ul 
aliquot) fractions were separated on a 12.5% SDS-PAGE gel and visu- 
alised by staining with Coomassie blue. Panel (a) shows the im- 
munoprecipitated proteins and panel (b) shows the supernatants. Num- 
bers above lanes indicate the amount (in/,tg) of GST-p53BP2 added to 
the extracts. Markers (M) are in kDa. Arrows in (a) indicate the im- 
munoprecipitated GST-p53BP2 and PP1 y~ and in (b) the GST-p53BP2 
added to, and the GST expressed in, the E. coil extracts. 
2.6. hnmunoprecipitation a d glutathione-affinity methods 
Immunoprecipitation experiments were performed in 50 or 100/A of 
50 mM Tris-HCl pH7.5, containing 150 mM NaC1, 0.1% (v/v) 2-mer- 
captoethanol, 0.02% (v/v) Brij 35 and 0.1 mg/ml bovine serum albumin 
(BSA). Indicated amounts of interacting proteins were incubated inthis 
buffer for 1 h at 4°C, then 10 pl of anti-EFMPME-Sepharose added 
and incubation at 4°C was continued with shaking for 1 h. After 
centrifugation, the supernatant was removed and the pellet was washed 
twice with 1 ml of buffer (lacking BSA), then denatured by heating in 
SDS-PAGE loading buffer at 95°C for 5 min. Glutathione-affinity 
precipitations were performed in an identical manner except hat anti- 
EFMPME-Sepharose was replaced by glutathione-agarose (Sigma). 
2.7 Protein phosphatase assays 
;:P-labelled rabbit skeletal muscle glycogen phosphorylase was pre- 
pared as described in [27]. Chicken gizzard smooth muscle myosin 
P-light chains expressed in bacteria were a gift from Dr J. Kendrick- 
Jones (MRC Laboratory of Molecular Biology, Cambridge) and 
phosphorylated by Miss Deborah Johnson (University of Dundee) 
using myosin light chain kinase kindly provided by Dr M. Ikebe (De- 
partment of Physiology and Biophysics, Case Western Reserve Univer- 
sity, Cleveland, USA). The specific activity of the [y-32p]ATP used for 
6 all phosphorylations was 10 cpm/nmol. The native catalytic subunit of 
PPI (PPlc) was purified from rabbit skeletal muscle by Dr G. 
Moorhead (University of Dundee). Protein phosphatase assays were 
performed in the absence of divalent cations [27] using the above sub- 
strates. One unit of phosphatase activity is that amount of enzyme 
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which catalyses release of I ,umol [~-~P]phosphate/min from ;2P-labelled 
substrate in the standard assay. 
3. Results 
3.1. Isolation af human p53BP2 eDNA using expressed human 
PPlyl  in the yeast two hybrid system 
Proteins capable of interacting with PP1 y~ were identified in 
yeast cells containing a pASPPlyt construct in which PP1z~ 
was fused to the DNA binding domain of GAL4 [18]. These 
cells were transformed with DNA from a pACT library con- 
taining human peripheral lymphocyte cDNA sequences [28] 
fused to the GAL4 transactivation domain. After growth on the 
selection medium for twelve days, ten colonies were obtained, 
representing 0.005% of the cells transformed [18]. Of the colo- 
nies which were taken through another ound of selection on 
medium containing 3-aminotriazole and also shown to possess 
fl-galactosidase activity, two contained overlapping sequences 
coding for human p53BP2 [19]. One, termed PPIH1, encoded 
amino acids 239-529 and the second, termed PPIH8, amino 
acids 297- 529. Both clones also possessed the entire 3' untrans- 
lated region of p53BP2 identical to that reported in [19]. 
3.2. Co-immunoprecipitation of human p5 3 B P2 and human P P I 
Since the signal in the two hybrid assay could have been 
mediated by artifactual interactions, we sought to confirm the 
binding ofp53BP2 to PP1 by immunoprecipitation studies. For 
these experiments the coding region from the longest clone. 
PPIH1, was subcloned into pGEX-3X to produce a fusion 
protein of glutathione-S-transferase (GST) linked to p53BP2. 
To test the specificity of the interaction, varying amounts of the 
purified fusion protein were added to crude extracts of E. coli. 
containing approximately 0.15 mg/ml GST, followed by addi- 
tion of epitope-tagged PP 1 y]. Immunoprecipitation of the com- 
plexes with antibodies to the EFMPME epitope (coupled to 
protein G-Sepharose beads) is shown in Fig. 1. The data dem- 
onstrate that the interaction of p53BP2 and PPI is extremely 
specific, in that p53BP2 is the only protein immunoprecipitated 
by the PPl-antibody complex from crude extracts containing 
as little as 100 ng of GST-p53BP2. No GST (26 kDa), which 
was present in a large (3 300 fold) excess over p53BP2, was 
observed in the immunoprecipitates. The approximately equal 
intensity of p53BP2 and PPI in the immunoprecipitates indi- 
cates that the interaction is near stoichiometric. In order to 
investigate the stability of the p53BP2-PPI complex, im- 
munoprecipitations were performed at varying salt concentra- 
tions. Fig. 2 shows that the interaction of p53BP2 with PPlyL 
is stable in concentrations of NaC1 up to and including l M. 
In contrast, the complex of p53 with p53BP2 was present at 250 
mM NaC1, but disrupted in concentrations of 0.5 M NaCI or 
higher (Fig. 2). No binding of p53 to PP1 was seen at any NaCI 
concentration used. 
3.3. Identification of the site oJ interaction ~/p53BP2 ~,ith PPI 
The fragment of p53BP2 comprising amino acids 297 529 
(encoded by clone PP1HS) binds equally well to PPI as the 
fragment of p53BP2 comprising amino acids 239- 529 (encoded 
by clone PPIH1) (Fig. 3b), indicating that amino acids 239 297 
are not required for the interaction. The region of p53BP2 
encoded by both these clones contains two ankyrin repeats and 
a SH3 domain (Fig. 3a). In order to determine which of these 
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Fig. 2. Stability of the p53BP2-PPl complex to NaC1. 50/tl reaction 
volumes containing 1/lg of each test protein and the stated amount of 
NaCI were precipitated as described in section 2 using either anti- 
EFMPME antibodies (PP1T~ + p53) or glutathione-agarose (p53 + 
p53BP2 and PPIy~ + p53BP2). Wash buffers contained the same con- 
centrations of NaC| as the incubation buffers. Pellet fractions were 
separated on a 10% SDS-PAGE gel and visualised by staining with 
Coomassie blue. Lanes are: (1-4), PPly~ + p53; (5-8), p53 + p53BP2; 
(9 12), PPly~ + p53BP2. NaC1 concentrations were 250 mM in lanes 
(1,5,9), 500 mM in lanes (2,6,10), 750 mM in lanes (3,7,11) and 1 M in 
lanes (4,8,12). Markers (M) are in kDa. Arrows indicate the im- 
munoprecipitated GST-p53BP2, p53 and PPly~. 
regions was necessary for binding to PP 1, a construct, PP1H 1A, 
was generated in which DNA encoding the SH3 domain was 
deleted from the PP1H1 clone (Fig. 3a). The resulting fragment 
of p53BP2 comprising amino acids 239-431 could also be co- 
immunoprecipitated with PP1 (Fig. 3b), indicating that the SH3 
domain is not essential for binding. Interestingly, both 
p53BP2(239-529) and p53BP2(239-431) migrate anomonously 
on SDS-PAGE, with apparent molecular masses larger than 
predicted from their amino acid sequences. The proline-rich 
amino-terminal region of these fragments may underlie this 
effect because p53BP2(297 529), which does not contain this 
region, migrates on SDS-PAGE with an apparent molecular 
mass consistent with its predicted size. 
3.4. p53BP2 modulates the specificity of PP1 
Several regulatory subunits of PP1 are known to modulate 
its activity [10]. The effect of p53BP2 on the activity of the 
native PPI catalytic subunit (PP I c) purified from rabbit skeletal 
muscle was therefore xamined. Fig. 4a shows that nanomolar 
concentration of p53BP2 (239-529) virtually eliminate PP1 ac- 
tivity towards the standard substrate normally used to assay 
PP1, glycogen phosphorylase. This inhibition occurs in the 
same concentration range as other modulators of PP1 activity, 
such as inhibitor-2. In contrast, p53BP2 has virtually no effect 
on (or slightly enhances) the activity of PP1 towards myosin 
P-light chains, demonstrating that p53BP2 is not a non-specific 
inhibitor of PP1. There was no effect of p53BP2 at 1 gtM on 
lhe phosphorylase phosphatase and myosin light chain phos- 
phatase activities of PP2A (data not shown). 
3.5. p53 and PPI binding to p53BP2 is mutually exclusive 
In order to investigate whether p53, p53BP2 (239-529) and 
PP1 can form a ternary complex, we added increasing concen- 
trations of PP1 to a complex of p53 and p53BP2. As shown in 
Fig. 5, this resulted in loss of p53 binding to p53BP2. However, 
addition of p53 caused little dissociation of the p53BP2-PPII/] 
complex over the concentration range used. This result is con- 
sistent with the relative stabilities of the two complexes to high 
concentrations of NaCI (Fig. 2). 
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Fig. 3. Identification of the region of p53BP2 which binds to PP1. (a) Schematic diagram of the region of p53BP2 which interacts with PPI y~. p53BP2 
fragments identified in the two hybrid screen (from clones PP1H1 and PP1H8) and p53BP2 truncated at the C-terminus (expressed from clone 
PP1H IA) are aligned with the longest known p53BP2 sequence. Numbers indicate amino acid positions with respect to the original p53BP2 sequence. 
Positions of the ankyrin repeats and SH3 domain are indicated. (b) Immunoprecipitation of GST-p53BP2 fusion proteins with epitope-tagged PP 1Yl. 
50/ll reactions containing 2 ,ug of GST-p53BP2 fusion proteins plus or minus 2/~g of PP1 ?'~ were precipitated as described in materials and methods 
using anti-EFMPME antibodies. Pellet fractions were separated on a 10% SDS-PAGE gel and visualised by staining with Coomassie blue. Lanes 
are: (1,5) GST; (2,6) GST-p53BP2 (239-529); (3,7) GST-p53BP2 (297-529): (4,8) GST-p53BP2 (239431). Lanes (5 8) contained epitope-tagged 
PPIy~. Markers (M) are in kDa. Arrows indicate the immunoprecipitated GST-p53BP2 fragments and PP1T~. 
4. Discussion 
We have identified the p53 binding protein p53BP2 as a 
protein that interacts with PPI in the yeast two hybrid system. 
The finding that two different clones both encoding p53BP2 
were among the ten positive clones isolated using the two hy- 
brid screen strengthened the likelihood that the interaction of 
p53BP2 with PPI is not an artifact. The specificity of the inter- 
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Fig. 4. Effect of p53BP2 on the phosphatase activity of PP1 catalytic subunit. Assays were performed with the catalytic subunit of PP1 (PPlc) at 
0.16 mU/ml and included GST or GST-p53BP2 (239-529) in the concentration range (0-1 ,uM). Protein phosphatase activity is plotted as a percentage 
of the activity observed when no GST or GST-p53BP2 (239 529) is present. Panels how dephosphorylation of 32P-labelled substrates, (a) phosphory- 
lase and (b) myosin P-light chain. 
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Fig. 5. Binding of PPl and p53 to p53BP2 is mutually exclusive. 50/~l 
reactions containing 1/~g of GST-p53BP2 (239 529). 2 j~g of either 
PPly~ or p53 and varying amounts of competing protein were precipi- 
tated using glutathione agarose. Pellet fractions were separated on a 
12.5% SDS-PAGE gel and visualised by staining with Coomassie blue. 
Lanes 1 5 contain GST-p53BP2 and p53 plus varying amounts of 
PPlyl, (lane 1) 0/~g, (lane 2) 0.1/~g, (lane 3) 0.5/zg, (lane 4) 1 /lg and 
(lane 5) 5/zg; lanes (~10 contain GST-p53BP2 and PPI)'~ plus varying 
amounts of p53, (lane 1) 0/lg, (lane 2) 0.1 ]~g, (lane 3) 0.5 ,ug, (lane 4) 
1/lg and (lane 5) 5/~g. Markers (M) are in kDa. Arrows indicate the 
immunoprecipitated GST-p53BP2, p53 and PPly~. 
action was confirmed by near stoichiometric co-precipitation 
of bacterially expressed p53 BP2 and PP 1 from low levels (< 100 
ng ofp53BP2) in crude E. coil extracts, p53BP2 appears to bind 
more strongly to PPI than to p53, since the p53BP2-PPI com- 
plex was stable to 1M NaCI while the complex of p53BP2 and 
p53 was disrupted in 0.5M NaC1. Our data also show that PPI 
and p53 cannot bind simultaneously to p53BP2, since no evi- 
dence for formation of a ternary complex was obtained. This 
suggests that p53BP2 is more likely to exist in a complex with 
PPI in the cell than with p53. p53BP2 has been shown to 
interact with the central sequence-specific DNA binding do- 
main of p53 and particular amino acid residues in p53 have 
been shown to be crucial to this interaction [19, 29]. It is there- 
fore possible that PP1 binds to the region of p53BP2 that 
interacts with this domain of p53 or, alternatively, PPI might 
bind elsewhere and alter the contk)rmation fp53BP2 such that 
it cannot bind to p53. 
The region of p53BP2 which binds to both p53 [19] and PPI 
contains two ankyrin repeats and an SH3 domain. Deletion of 
the SH3 domain did not affect the interaction of p53BP2 with 
PP1, implicating the section (amino acids 297 431) containing 
the ankyrin repeats as being essential for PP1 binding. It is of 
interest that smooth muscle M~tu myosin binding subunit hat 
interacts with PPI contains even ankyrin repeats [13]. 
The strongest evidence that lk~rmation of a complex of 
p53BP2 and PP1 might be functionally important in vivo comes 
from the effect of p53BP2 on PPI activity. The interaction or" 
p53BP2 with PP1 almost abolished its activity towards glyco- 
gen phosphorylase, but intriguingly, does not abolish its activ- 
ity towards myosin P-light chains. This indicates that p53BP2 
is likely to have a selective ffect on the substrate specificity of 
PP1, as has been noted for other regulatory subunits of PP1. 
For example, the M Ltu subunit decreases the phosphorylase 
phosphatase activity of PPl and enhances its myosin P-light 
chain phosphatase activity [22]. In contrast, the cytosolic pro- 
tein, inhibitor-2, inhibits both the phosphorylase phosphatase 
and myosin P-light chain phosphatase activity of PP1, but has 
little effect on the dephosphorylation of histone H I [22]. Thus 
p53BP2 affects the specificity of PP1 in a different manner from 
other known regulatory subunits. 
There is considerable evidence that phosphorylation plays a 
role in the regulation of p53. The p53 protein is phosphorylated 
by a large number of kinases in vitro, including protein kinase 
C and casein kinase II which activate the sequence specific 
binding of p53 to DNA [9]. However, the nature of the phos- 
phatase responsible for the dephosphorylation of these sites is 
unclear. It is possible that, just as other regulatory subunits of 
PPI enhance its activity towards certain substrates, the function 
of p53BP2 is to enhance PP1 dephosphorylation of p53 in the 
nucleus and inhibit PP1 activity against other substrates. The 
failure of p53, a fragment of p53BP2 and PPI to form a ternary 
complex in the present work might argue against he idea that 
p53BP2 targets PP1 to p53. However, the bacterially expressed 
p53 used in these studies is not phosphorylated, It is also pos- 
sible that covalent modification of p53BP2 may lead to forma- 
tion of ternary complexes or that native full-length p53BP2 
might interact with p53 in such a way that a ternary complex 
can be formed in vivo. However, many other alternatives still 
need to be explored. For example, SH3 domains play promi- 
nent roles in a number of cellular signalling processes, raising 
the possibility that the SH3 domain of p53BP2 may couple PP1 
dephosphorylation of p53 to cell signalling events. Other possi- 
bilities that need to be considered are whether p53BP2 targets 
PPI-p53 to particular nuclear locations, or whether PPI plays 
a role in regulating the function of p53BP2 itself. 
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